ArticleThe Journal of international medical research2026
Correlation of triglyceride glucose-body mass index, bedside index for severity in acute pancreatitis, and C-reactive protein-to-lymphocyte ratio with disease severity in patients with hyperlipidemic acute pancreatitis: A retrospective-cohort study.
Article in The Journal of international medical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A Novel Triple-Biomarker Score Predicts Mortality in Acute Pancreatitis.Gastroenterology research · 2026Article
- An Interpretable Machine Learning Model for Predicting in-Hospital Progression in Initially Mild Hypertriglyceridemia-Induced Acute Pancreatitis Using Clinical and Non-Contrast CT Features.International journal of general medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
ObjectiveThis study aimed to evaluate the correlations between the triglyceride glucose-body mass index, the bedside index for severity in acute pancreatitis score, and the C-reactive protein-to-lymphocyte ratio with disease severity, as well as their prognostic value, in patients with hyperlipidemic acute pancreatitis.MethodsThis retrospective cohort study analyzed 247 patients diagnosed with hyperlipidemic acute pancreatitis. Participants were stratified according to the 2012 Atlanta criteria into mild (n = 108), moderately severe (n = 71), and severe (n = 68) groups. Based on 28-day outcomes, patients were categorized into poor prognosis (n = 90) and good prognosis (n = 157) groups. We compared baseline data and performed Spearman correlation analysis, Cox univariate/multivariate regression, and receiver operating characteristic analysis.ResultsThe triglyceride glucose-body mass index, bedside index for severity in acute pancreatitis, and C-reactive protein-to-lymphocyte ratio significantly increased with disease severity (p < 0.05) and demonstrated strong positive correlations (p < 0.01). Multivariate Cox regression identified triglyceride glucose-body mass index (hazard ratios = 1.62, 95% confidence intervals: 1.33-1.97), bedside index for severity in acute pancreatitis (hazard ratios = 1.92, 95% confidence intervals: 1.43-2.57), and C-reactive protein-to-lymphocyte ratio (hazard ratios = 2.05, 95% confidence intervals: 1.62-2.60) as independent predictors of poor prognosis. The combination of all three markers yielded the highest predictive accuracy (area under the curve = 0.987) for predicting 28-day poor prognosis, a finding that was robust on internal validation.ConclusionsThe triglyceride glucose-body mass index, bedside index for severity in acute pancreatitis score, and C-reactive protein-to-lymphocyte ratio are valuable tools for assessing disease severity and predicting prognosis in hyperlipidemic acute pancreatitis. Their combined use may potentially enhance early risk stratification and guide clinical decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.